Aarti Pharmalabs Limited filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ending March 31, 2026, with the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 29, 2026. The filing complies with Regulation 34(2)(f) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company reported a turnover of ₹17,975.5 crore and a net worth of ₹19,740.9 crore for the period. The standalone report covers operations across 15 plants and three offices in India, serving customers in 51 countries. Exports accounted for approximately 55.93% of total turnover.

Operational and Financial Overview

Aarti Pharmalabs operates primarily in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The API segment contributed 51% of turnover, while xanthine derivatives contributed 49%. The company employs 2,033 permanent employees and 2,185 workers as of March 31, 2026.

Environmental Performance

The company disclosed significant reductions in energy intensity and greenhouse gas emissions per unit of turnover. Total energy consumption from non-renewable sources fell to 7,82,556.47 GJ from 12,99,598.24 GJ in the prior year. Scope 1 emissions decreased to 92,294.78 metric tonnes of CO2 equivalent, while Scope 2 emissions dropped sharply to 63,582.46 metric tonnes from 105,577.65 metric tonnes.

Aarti Pharmalabs implemented a Zero Liquid Discharge mechanism across all units, recycling 100% of liquid waste. The company also installed a 15 MW solar power plant in Akola, Maharashtra, which saved 84,393.32 GJ of energy during the fiscal year.

Governance and Social Metrics

The board comprises 12 directors, with women representing 33.3% of the membership. The company reported zero fatalities and zero lost-time injury frequency rates for both employees and workers. Training coverage reached 100% for all employees and workers on human rights issues.

The company paid a penalty of ₹2.6 lakh to the Office of the Assistant Commissioner, CGST and Central Excise, Vapi, regarding alleged excess availment of Input Tax Credit for FY23 and FY24. No appeals were preferred against this order.

What the Numbers Show

A notable divergence exists between the company's waste generation volume and its recycling efficiency. While total waste generated increased significantly to 26,229.55 metric tonnes from 15,550.04 metric tonnes in the prior year, the amount recycled more than doubled to 12,835.85 metric tonnes. This suggests that the rise in waste is largely associated with production scale-up that the existing recycling infrastructure can absorb, rather than a decline in waste management efficacy.

Aarti Pharma Labs has scheduled its seventh Annual General Meeting (AGM) for Tuesday, September 22, 2026. The meeting will commence at 11:00 am and will be conducted exclusively through Video Conferencing or Other Audio Visual Means (OAVM), without physical presence of shareholders at a common venue.

The company released the notice alongside the Annual Report for the financial year ending March 31, 2026 (FY26). In compliance with SEBI Listing Regulations and Ministry of Corporate Affairs circulars, the documents are being distributed primarily through electronic mode to shareholders with registered email addresses.

Digital Distribution and Access

Shareholders who have not registered email addresses with the company or their Depository Participants will receive letters containing web links to the annual report. The complete notice and annual report are also accessible on the company’s official website.

Corporate Governance

Jeevan Bhargav Mondkar, Company Secretary and Legal Head, signed the disclosure filed with both the Bombay Stock Exchange and the National Stock Exchange of India Limited. The filing references Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.